DanielJacobyMD

Cardiology • New Haven, CT

Heart Failure & Transplantation

Assistant Professor, Internal Medicine, Yale University School of Medicine

Join to view full profile

Dr. Jacoby is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jacoby's full profile

Already have an account?

Office
333 Cedar St
3 Fmp
New Haven, CT 06510
Phone+1 203-785-7191

Fax+1 203-785-2197

Education & Training

Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2000 - 2003
Yale School of MedicineClass of 2000

Certifications & Licensure

CT State Medical License 2007 - 2025
NY State Medical License 2001 - 2008

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amyloidosis in Medical Records Start of enrollment: 2024 Apr 01
Not yet recruiting
Not Applicable

Publications & Presentations

PubMed

317 citations
Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).
Mathew S. Maurer, Mazen Hanna, Martha Grogan, Angela Dispenzieri, Ronald M. Witteles
Journal of the American College of Cardiology. 2016-07-12
445 citations
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
Iacopo Olivotto, Artur Oreziak, Roberto Barriales-Villa, Theodore P. Abraham, Ahmad Masri
Lancet. 2020-09-12
95 citations
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlle...
John A. Spertus, Jennifer T. Fine, Perry M. Elliott, Carolyn Y. Ho, Iacopo Olivotto
Lancet. 2021-06-26

Journal Articles

Left Atrial Fibrosis Correlates with Extent of Left Ventricular Myocardial Delayed Enhancement and Left Ventricular Strain in Hypertrophic Cardiomyopathy
Albert J Sinusas, Vinh Q Nguyen, Nikolaos Papoutsidakis, David J Hur, Jeffrey Testani, Hamid Mojibian, Judith L Meadows, Daniel Jacoby, Steffen Huber, The International Journal of Cardiovascular Imaging

Press Mentions

Health Canada Approves Camzyos(TM) (Mavacamten Capsules) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic CardiomyopathyNovember 11th, 2022
Pilot Project Funding Offered by the Yale Center for Healthcare Innovation and the Section of Cardiovascular MedicineAugust 6th, 2021
Marvin A SteinbergJanuary 29th, 2021
Join now to see all

Professional Memberships

American College of Cardiology - ACC
Member